menu
    • menu
    [{"orgOrder":0,"company":"Myosin Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MT-125","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Myosin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myosin Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Myosin Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Myosin Therapeutics","sponsor":"DeepWork Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"MT-125","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Myosin Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Myosin Therapeutics \/ DeepWork Capital","highestDevelopmentStatusID":"6","companyTruncated":"Myosin Therapeutics \/ DeepWork Capital"},{"orgOrder":0,"company":"Myosin Therapeutics","sponsor":"Mint12 Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"MT-125","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Myosin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myosin Therapeutics \/ Mint12 Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Myosin Therapeutics \/ Mint12 Pharma"},{"orgOrder":0,"company":"Myosin Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"MT-125","moa":"Non-Muscle Myosin II","graph1":"Oncology","graph2":"Phase I","graph3":"Myosin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myosin Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Myosin Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Myosin Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"MT-110","moa":"T-cell surface glycoprotein CD3 epsilon (CD3E)","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Myosin Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myosin Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Myosin Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Myosin Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MT-125","moa":"Non-Muscle Myosin II","graph1":"Oncology","graph2":"Phase I","graph3":"Myosin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myosin Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"6","companyTruncated":"Myosin Therapeutics \/ Mayo Clinic"}]

    Find Clinical Drug Pipeline Developments & Deals by Myosin Therapeutics

    Menu

    Myosin Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Myosin Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Myosin Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MT-125

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Mayo Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of the Safety and Tolerability of MT-125 in GBM Patients

                            Details : MT-125 is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 22, 2025

                            Lead Product(s) : MT-125

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Mayo Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Myosin Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Myosin Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MT-125

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : National Cancer Institute

                            Deal Size : $4.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Myosin Awarded $4.5 Million NCI Bridge Grant to Advance Phase I of MT-125 in Glioblastoma

                            Details : The funding will support Phase I dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with glioblastoma.

                            Product Name : MT-125

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 19, 2025

                            Lead Product(s) : MT-125

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : National Cancer Institute

                            Deal Size : $4.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Myosin Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Myosin Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MT-125

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Myosin Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma

                            Details : MT-125 is a selective inhibitor of non-muscle myosin II (NMII), designed to disrupt critical mechanisms of glioblastoma progression.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 09, 2025

                            Lead Product(s) : MT-125

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Myosin Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Myosin Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MT-110

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Myosin gets $3M NIH Grant to Advance MT-110 Trial for Meth use Disorder

                            Details : The grant will help support the initiation of a Phase 1 clinical trial to assess the safety, tolerability of MT-110, as a first-in-class treatment option for methamphetamine use disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 28, 2025

                            Lead Product(s) : MT-110

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Myosin Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Myosin Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MT-125

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : DeepWork Capital

                            Deal Size : $52.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Myosin Closes Seed Round to Advance Cancer & Neuroscience Clinical Trials

                            Details : The company intends to advance its lead compound, MT-125, which targets a molecular nanomotor, to treat glioblastoma, the most aggressive brain cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 03, 2025

                            Lead Product(s) : MT-125

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : DeepWork Capital

                            Deal Size : $52.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Myosin Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Myosin Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MT-125

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Mint12 Pharma

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Myosin Therapeutics Closes Seed Round to Continue Development of Innovative Therapies for Glioblastoma and Sti...

                            Details : Myosin Therapeutics will use the financing to advance and develop MT-125, to treat glioblastoma, which is a highly aggressive form of brain cancer with a 95% fatality rate and limited treatment options available.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 14, 2023

                            Lead Product(s) : MT-125

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Mint12 Pharma

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth